Sana Biotechnology
SANA
105 hedge funds and large institutions have $1.73B invested in Sana Biotechnology in 2021 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 41 increasing their positions, 13 reducing their positions, and 11 closing their positions.
215% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 13
173% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 11
19% more funds holding
Funds holding: 88 → 105 (+17)
0.56% more ownership
Funds ownership: 58.53% → 59.08% (+0.56%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
22% less call options, than puts
Call options by funds: $398K | Put options by funds: $511K
30% less capital invested
Capital invested by funds: $2.48B → $1.73B (-$751M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$17M |
| 2 |
BlackRock
New York
|
+$16.8M |
| 3 |
JP Morgan Chase
New York
|
+$7.53M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.84M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$17.4M |
| 2 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$13.4M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$9.07M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$3.42M |
| 5 |
Morgan Stanley
New York
|
-$3.23M |
SANA Hedge Fund Activity: Q4 2021 in Review
105 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q4 2021, worth a combined $1.73B — down 30% from $2.48B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new SANA positions and 11 closed out — a net gain of 19 holders — while 41 added to existing stakes and 13 trimmed.
The largest buyer was State Street, adding an estimated $17M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $17.4M sold.
- 105 institutional investors held Sana Biotechnology (SANA) as of Q4 2021, up from 88 in Q3 2021.
- Funds reported $1.73B of Sana Biotechnology stock for Q4 2021, down 30% quarter-over-quarter.
- 30 funds opened new Sana Biotechnology positions in Q4 2021 and 11 closed out, a net change of +19 holders.
- The largest Sana Biotechnology buyer in Q4 2021 was State Street, an estimated $17M added.
- The largest Sana Biotechnology seller in Q4 2021 was Avidity Partners Management, an estimated $17.4M sold.
Based on aggregated 13F filings for Q4 2021.